Transplant patients may get simpler Once-Daily pill regimen

NCT ID NCT02882828

Completed Disease control Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

First seen Nov 21, 2025 · Last updated May 26, 2026 · Updated 25 times

Summary

This study looked at 134 kidney or liver transplant patients to see if switching from a twice-daily anti-rejection drug (Prograf) to a once-daily version (Envarsus) keeps drug levels stable. Researchers used blood tests and computer models to compare exposure. The goal is to make dosing easier while maintaining safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLOGRAFT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AP-HP

Paris, France
Limoges Hospital

Limoges, 87 042, France
University Hospital of Amiens

Amiens, France
University Hospital of Bordeaux

Bordeaux, France
University Hospital of Lille

Lille, France
University Hospital of Poitiers

Poitiers, France
University Hospital of Reims

Reims, France
University Hospital of Rouen

Rouen, France
University Hospital of Tours

Tours, France

Conditions

Explore the condition pages connected to this study.

ALLOGRAFT